IDE Recombinant Monoclonal Antibody

中文名稱(chēng)：

IDE Recombinant Monoclonal Antibody
貨號(hào)：

CSB-RA784916A0HU
規(guī)格：

￥1320
圖片：
Flow cytometric analysis of IDE expression in HepG2 cells using IDE antibody. Green, isotype control; red, IDE.

Western blotting analysis using IDE antibody. Total cell lysates (30 μg) from various cell lines were loaded and separated by SDS-PAGE. The blot was incubated with IDE antibody and HRP-conjugated goat anti-rabbit secondary antibody respectively.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P14735
基因名：

IDE
別名：

IDE; Insulin Degrading Enzyme; Insulin-Degrading Enzyme; Antibodyeta-Degrading Protease; Insulin Protease; EC 3.4.24.56; Insulinase; Insulysin; INSULYSIN; EC 3.4.24
反應(yīng)種屬：

Human, Mouse, Rat
免疫原：

Recombinant Human IDE protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類(lèi)型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

17H9
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in PBS (pH 7.4) containing 50% glycerol, and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, FC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
FC	1:200-1:2000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Flow cytometry (FC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, natriuretic peptides, glucagon, bradykinin, kallidin, and other peptides, and thereby plays a role in intercellular peptide signaling. Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin. Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP. Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia (Probable). Degrades the natriuretic peptides ANP, BNP and CNP, inactivating their ability to raise intracellular cGMP. Also degrades an aberrant frameshifted 40-residue form of NPPA (fsNPPA) which is associated with familial atrial fibrillation in heterozygous patients. Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I.; (Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).
基因功能參考文獻(xiàn)：
1. These results support the hypothesis that IDE gene expression in different areas of Alzheimer's patient's brains. PMID: 28164769
2. People with allelic variation in four genes related to cardiovascular diseases and metabolism were more likely to die: apolipoprotein (APO)C1 GG and AG carriers, APOE varepsilon4 carriers, insulin-degrading enzyme (IDE) TC carriers, and phosphatidylinositol 3-kinase (PI3KCB) GG carriers. PMID: 27806189
3. Data suggest the possibility of development of insulin-degrading enzyme (IDE)-based drugs for the treatment of the late-onset form of Alzheimer's disease (AD). PMID: 27982586
4. the mechanistic and molecular features of IDE-26S proteasome interaction in a cell experimental model, is reported. PMID: 26186340
5. No significant associations have been found between other IDE gene single nucleotide polymorphisms of rs4646953, rs2251101 and rs1544210 with Alzheimer disease. PMID: 25105907
6. results demonstrate that the polymorphisms rs1887922 and rs1999764 of the IDE gene are associated with late-onset Alzheimer disease susceptibility in the Xinjiang Han population PMID: 25414272
7. Cognitive impairment is more frequent among those exposed to the C allele of the rs2209972 SNP of the insulin degrading enzyme gene. PMID: 24355596
8. IDE does not play a major role in MHC class I antigen processing, confirming the dominant and almost exclusive role of the proteasome in cytosolic production of MHC class I ligands. PMID: 24516642
9. using combinational in silico investigations, study identified that pathogenic nonsynonymous mutations corresponding to p.I54F, p.P122T, p.T533R, p.P581A and p.Y609A have more potential role in structural and functional deviations of IDE activity PMID: 24059301
10. Our study provided evidence to IDE, PON1, WFS1, POU2F1, IL1alpha and IL1beta associated with T2D in Pakistanis. PMID: 24477584
11. An upstream promoter element which blocks the antisense transcription of the human IDE promoter, was identified. PMID: 23797320
12. Both IDE and type 2 diabetes are associated with executive function levels in older adults PMID: 23597493
13. Conformational changes in IDE, including a swinging-door mechanism that permits the entry of short peptides into the catalytic chamber, governs the selective destruction of amyloidogenic peptides. PMID: 23922390
14. for the rs1832196 polymorphism, significant association with Alzheimer disease was found by the dominant model in overall and subgroup analysis. PMID: 23416320
15. IDE-Met(1) links the mitochondrial biogenesis pathway with mitAbeta levels and organelle functionality. PMID: 23525105
16. Genetic variants for both insulin degrading enzyme (IDE) and angiotensin converting enzyme (ACE) in relation to cognitive phenotype. PMID: 21232820
17. In the context of APOEepsilon4-negative status, insulin-degrading enzyme variants are significantly associated with Alzheimer disease in some genetic models. PMID: 22502914
18. The polymorphism of insulin-degrading enzyme is associated with susceptibility to Alzheimer's disease in Han Chinese. PMID: 20880607
19. Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. PMID: 22267728
20. The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Abeta42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9. PMID: 22107728
21. Significant differences were found in the response to induced ketosis among non-carriers of putative gain-of-function polymorphisms in rs1143627 and rs16944 in the IL-1beta gene and among variants of the polymorphism rs2251101 in the insulysin gene. PMID: 21992747
22. BRI2 protein regulates beta-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). PMID: 21873424
23. Five IDE variants for altered in vitro reporter gene expression, based on their presence on haplotypes (H2, H6 and H9) and their association with altered IDE mRNA transcript levels , were tested. PMID: 21731745
24. dimers of insulin-degrading enzyme reveal a cis activation mechanism PMID: 21343292
25. IDE cleaves ubiquitin in a biphasic manner PMID: 21185309
26. the evolutionarily conserved IDE may play a key role in modulating and reshaping the strength and duration of NP-mediated signaling. PMID: 21098034
27. IIA(Glc) of the sugar phosphotransferase system regulates the peptidase activity of a mammalian insulysin homolog in V. vulnificus. PMID: 20971110
28. Insulin degrading enzyme is linked with aggregated Abeta40 isoform while neprilysin negatively correlates with amyloid angiopathy. PMID: 19019493
29. IDE is not correlated with amyloig beta or clinical diagnosis Alzheimer disease PMID: 20663017
30. produce tumor antigenic peptides presented by MHC class I molecules for cytotoxic T lymphocyte recognition PMID: 20364150
31. the catalytic mechanisms for the hydrolysis of the three different peptide bonds of Alzheimer amyloid beta (Abeta) peptide by insulin-degrading enzyme (IDE) PMID: 20033747
32. this study more generally suggests an interplay between RB and IDE within the proteasome that may have important growth-regulatory consequences. PMID: 20362553
33. Results describe the in vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme. PMID: 20082125
34. In comparison to Abeta40, Abeta42 is more flexible and interacts through a smaller number (17-22) of hydrogen bonds in the catalytic chamber of IDE. PMID: 20380468
35. a previously unreported variant unequivocally associated with increased IDE expression was also associated with reduced plasma Abeta40 and decreased LOAD susceptibility PMID: 20098734
36. Study verified associations of two IDE polymorphisms (rs1887922 and rs2149632) with type 2 diabetes risk in two independent German cohorts and evaluated in detail the association of common variants with insulin metabolism and glycemic traits. PMID: 19809796
37. structural basis of how the high dipole moment of substrates complements the charge distribution of the IDE catalytic chamber for the substrate selectivity PMID: 19896952
38. IDE protease binds to the 73-kDa gE precursor and that this event occurs in the cytosol but not as a receptor/ligand interaction. PMID: 19864391
39. possible mechanism by which the insulin-degrading enzyme (IDE) zinc-binding protease carries out its catalytic function toward two peptides of different length PMID: 19785409
40. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). PMID: 11809755
41. analysis of over 2,400 samples provides no compelling evidence that variation in IDE contributes to diabetes susceptibility in humans PMID: 12716770
42. when intracellular long-chain fatty acid concentrations are elevated, they may act directly on insulin-degrading enzyme to decrease insulin metabolism and alter insulin action in intact cells and this mechanism may contribute to insulin resistance PMID: 12746301
43. Polymorphism in this enzyme are associated with NIDDM in men. PMID: 12765971
44. IDE gene polymorphisms do not confer susceptibility to early- or late-onset AD at least in a Japanese population. PMID: 14755451
45. Biochemical characteristics of insulin degradation in wound fluid were consistent with characteristics of insulin-degrading enzyme. Reduction in insulin-degrading activity in wound fluid is potential therapeutic target. PMID: 14764804
46. genomic region in the proximity of IDE that may contribute to Alzheimer and Parkinson disease in a similar manner. PMID: 15088150
47. IDE gene promoter region variants are associated with AD in subjects without an epsilon4 allele PMID: 15181249
48. Polymorphism in/near IDE contributes to a large proportion of variance in plasma insulin levels and correlated traits. PMID: 15277398
49. The C allele of single-nucleotide polymorphism IDE2 associated with Alzheimer disease. There may be a possible synergic interaction between IDE & APOE epsilon4. PMID: 15277615
50. a defect in Abeta proteolysis by IDE contributes to the accumulation of this peptide in the cortical microvasculature PMID: 15489232
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm, cytosol. Cell membrane. Secreted. Note=Present at the cell surface of neuron cells. The membrane-associated isoform is approximately 5 kDa larger than the known cytosolic isoform.
蛋白家族：

Peptidase M16 family
組織特異性：

Detected in brain and in cerebrospinal fluid (at protein level).
數(shù)據(jù)庫(kù)鏈接：

HGNC: 5381

OMIM: 146680

KEGG: hsa:3416

STRING: 9606.ENSP00000265986

UniGene: Hs.500546

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human